Drug Information Association Logo
Corporate Tagline

Assessing the Benefits and Risks of Medicines: Webinar Series- Part 5: Stated Choice Methods for Valuing Benefits and Risks

Apr 24 2013 11:00AM - Apr 24 2013 12:30PM | Online

« Back to Listing

Overview 

Benefit-Risk 8-Part Webinar Series Overview

Plan now on participating in this webinar series to learn more about current approaches to Benefit-Risk (B-R) assessment, including how to:

  • Develop an understanding of the current B-R assessment initiatives and requirements
  • Assess how scientific approaches applied in other fields may be employed as an aid to structured and transparent decision analysis in the field of medicinal products
  • Discuss approaches and methods to enhance transparency and communication of B-R decisions
  • Identify opportunities and challenges of implementing exploratory approaches to B-R assessment
  • Identify and discuss processes and methods that may enhance B-R decision making, with the ability to:
    • Engage multiple perspectives
    • Quantify values
    • Evaluate the impact of uncertainty
    • Incorporate preference analysis and measurement
    • Provide greater infrastructure and consistency
    • Increase transparency

Assessing the Benefits and Risks of Medicines: Webinar Series Learning Objectives

  • Describe the current status of B-R assessment and key initiatives
  • Discuss approaches to perform B-R assessment to support and inform decision making
  • Identify uses for B-R assessment, such as regulatory decision-making or communication with patients


Overview Part 5:

This webinar will introduce participants to the use of stated-choice methods for eliciting Benefit-Risk trade-off preferences from key stakeholders and the use of these preferences to calculate risk tolerance.

 

Who Should Attend 

Professionals involved in:

  • Clinical Safety/Pharmacovigilance
  • Risk Management/REMS
  • Pharmacoepidemiology
  • Regulatory Affairs
  • Legal Affairs
  • Medical Affairs
  • Medical product safety assessment
  • Marketing
  • Clinical Research
  • Medical Communications
  • Statistics
  • Comparative Effectiveness/HTAs/Health Outcomes
  • Brand Commercial Teams

Additionally:

  • Regulators facing complex benefit-risk (B-R) decisions, as well as regulatory and drug development policy makers
  • Industry scientists involved in the evaluation of the B-R assessment of products in development or marketed products
  • Patient representatives and advocates who wish to have greater representation of their needs and concerns in decision making
  • Those wishing to learn more about the science and application of B-R assessment

Learning Objectives 

Learning Objectives Part 5:

At the conclusion of this webinar, participants should be able to:

  • Explain the concepts of conjoint analysis and stated choice methods
  • Discuss how the results can be used to assist decision makers in understanding the relative importance of benefits and risks to key stakeholders

Special Offers 

Register for two or more from this series and get 15% off!

Contact Information 

Registration Questions
Marilyn Ginsberg, Customer Service Associate
Phone +1.215.442.6135
Fax +1-215.442.6199
Marilyn.Ginsberg@diahome.org

Agenda and Event Details
Colleen Braun, Content Lead
Phone +1.215.442.6160
Fax +1.215.442.6199
Colleen.Braun@diahome.org

 Ellen Diegel, Event Planner
Phone +1.215.293.5810
Fax +1.215.442.6199
Ellen.Diegel@diahome.org

Technical Requirements 

Click here for minimum system requirements.

Presenter(s) 

Previous Next

Continuing Education 

The Drug Information Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is designated for 1.5 contact hours or .15 continuing education units (CEU’s). 0286-0000-13-040-L04-P; Type of Activity: Knowledge

ACPE Credit Request Update
DIA is required by the Accreditation Council for Pharmacy Education (ACPE) to report pharmacy-requested CEUs through the CPE Monitor system. All ACPE-certified activity credit requests need to be submitted through DIA’s My Transcript within 45-days post activity. Pharmacists will need to provide their National Association of Boards of Pharmacy (NABP) e-Profile ID and date of birth (MMDD) to ensure the data is submitted to the ACPE and NABP properly. If you need to obtain your NABP e-Profile, please visit www.cpemonitor.net.

Drug Information Association has been accredited as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 1760 Old Meadow Road, Suite 500, McLean, VA 22102 (703) 506-3275.

As an IACET Authorized Provider, Drug Information Association offers CEUs for its programs that qualify under the ANSI/IACET Standard. Drug Information Association is authorized by IACET to offer .2 CEUs for this program. Participants must attend the entire program in order to be able to receive an IACET statement of credit. No partial credit will be awarded.

This program is part of DIA’s Certificate Program and is awarded the following:
• Clinical Safety and Pharmacovigilance Certificate Program: 1 Elective Unit
• Regulatory Affairs Certificate Program: 1 Elective Unit
• Clinical Research Certificate Program: 1 Elective Unit
For more information go to www.diahome.org/certificateprograms

Name Credit Type Max Credits CEU
Benefit-Risk Series - Part 5 ACPE 1.50 0.150
Benefit-Risk Series - Part 5 IACET 1.50 0.200

Disclosure Policy:

It is DIA policy that anyone in a position to control the content of a continuing education activity must disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and/or the educational activity, and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. Disclosure statements will be included in the course materials.

Statement of Credit:

If you would like to receive a statement of credit, you must participate in the live webinar, and complete the online credit request process through My Transcript. To access My Transcript, please go to www.diahome.org, select “Login to My DIA” and you will be prompted for your user ID and password. Select “My Transcript” (left side bar) and “Credit Request” to process your credit request. Participants will be able to download a statement of credit upon successful submission of the credit request. My Transcript will be available for credit requests on Wednesday, May 8, 2013.

Continuing education credits are available to learners who participate in the live webinar. Continuing education credits are not available for the archived webinar.

To view DIA’s Grievance Policy, please visit the CE page on the DIA website at www.diahome.org/CE

Registration Fees 

Other Fees

Government (Full Time) Individual
$125.00
Charitable Nonprofit/Academia Individual
$175.00
Group Site
$799.00
Group Plus
$995.00

Member

Member Individual
$250.00

Non-Member

NonMember Individual
$295.00
Group Discounts

CANCELLATIONS
No refunds will be provided in the event of a participant’s cancellation since all costs for this webinar have been prepaid by DIA. DIA reserves the right to modify or cancel programs and/or substitute presenters or panelists. DIA is not responsible for failure to deliver programs due to circumstances beyond its control.

Participants with Disabilities Reasonable accommodations will be made available to persons with disabilities who attend an educational activity. Contact the DIA office in writing at least 15 days prior to event to indicate your needs.

Register Online

Unless otherwise disclosed, the statements made by speakers represent their own opinions and not necessarily those of the organization they represent, or that of the Drug Information Association. Speakers, agenda and CE information are subject to change without notice. Recording of any DIA educational material in any type of media is prohibited without prior written consent from DIA.

« Back to Listing Back To Top